| Technical Name | High-precision prediction method for EGFR-TKI efficacy | ||
|---|---|---|---|
| Project Operator | National Health Research Institutes Institute of Biomedical Engineering and Nanomedicine | ||
| Project Host | 李家惠 | ||
| Summary | To examine the expression levels of LDOC1 in EGFR mutated NSCLC tumors using IHC with customized anti-LDOC1 antibodies or using quantitative PCR methods. |
||
| Scientific Breakthrough | No previous studies have found a correlation between LDOC1 expression levels and the efficacy of EGFR-TKIs. Currently available anti-LDOC1 antibodies cannot be used for immunohistochemistry analysis. |
||
| Industrial Applicability | Pharmaceutical companies use this invention to select clinical trial patients and improve the efficacy of EGFR-TKI treatments. Manufacturers of proton or heavy ion therapy equipment encourage patients who do not respond to EGFR-TKIs to use proton or heavy ion therapy. Insurance companies use this invention to adjust policyholders’ premiums. Additionally, screening patients eligible for EGFR-TKI treatment under health insurance can save medical resources. |
||
| Keyword | EGFR-TKI LDOC1 IHC NSCLC EGFR mutated Iressa Tarceva treatment efficacy intrinsic EGFR-TKI resistance acquired EGFR-TKI resistance | ||
| Notes | |||
- Contact
- Chia-Huei Lee
- Chlee124@nhri.edu.tw
other people also saw
